{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:47:50Z","timestamp":1791874070946,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03067-w","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:44:19Z","timestamp":1791827059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging therapy in pediatric and AYA patients under 25 years with relapsed\/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-9664","authenticated-orcid":false,"given":"V\u00edctor","family":"Gal\u00e1n-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelaisy","family":"Le\u00f3n-Triana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-5470","authenticated-orcid":false,"given":"Anna","family":"Alonso-Saladrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazaret","family":"Sanchez-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-917X","authenticated-orcid":false,"given":"\u00c1gueda","family":"Molinos-Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7774","authenticated-orcid":false,"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-5716","authenticated-orcid":false,"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7586-4792","authenticated-orcid":false,"given":"M\u00f3nica","family":"Cabrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-8076","authenticated-orcid":false,"given":"Rafael","family":"Hernani-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-5451","authenticated-orcid":false,"given":"Berta","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Mart\u00ednez-Romera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Hong","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-0900","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"Balsalobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9195","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"3067_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375.","journal-title":"Ann Oncol"},{"key":"3067_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872\u201383.","journal-title":"Blood Adv"},{"key":"3067_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transpl. 2021;56:552\u201366.","journal-title":"Bone Marrow Transpl"},{"key":"3067_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306.","journal-title":"Blood"},{"key":"3067_CR5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650\u20139.","journal-title":"J Clin Oncol"},{"key":"3067_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2024.2406958","volume":"66","author":"Q Shang","year":"2025","unstructured":"Shang Q, Wang Y, Lu A, Jia Y, Zuo Y, Zeng H, et al. Impact of pre-infusion disease burden on outcomes in pediatric relapsed\/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy. Leuk Lymphoma. 2025;66:54\u201363.","journal-title":"Leuk Lymphoma"},{"key":"3067_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355.","journal-title":"J Clin Oncol"},{"key":"3067_CR8","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","volume":"35","author":"K Perica","year":"2021","unstructured":"Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021;35:3268\u201371.","journal-title":"Leukemia"},{"key":"3067_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","volume":"97","author":"Z Jin","year":"2018","unstructured":"Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, et al. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. 2018;97:1327\u201335.","journal-title":"Ann Hematol"},{"key":"3067_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"3067_CR11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"3067_CR12","first-page":"72.e1","volume":"28","author":"S Shahid","year":"2022","unstructured":"Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, et al. Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Transpl Cell Ther. 2022;28:72.e1\u201372.e8.","journal-title":"Transpl Cell Ther"},{"key":"3067_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100848","volume":"50","author":"TW Laetsch","year":"2021","unstructured":"Laetsch TW, Yanik GA, Boyer MW, Rheingold SR. An owner\u2019s manual for CD19 \u2018CAR\u2019-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. Blood Rev. 2021;50:100848.","journal-title":"Blood Rev"},{"key":"3067_CR14","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.3324\/haematol.2023.283780","volume":"109","author":"T Feuchtinger","year":"2024","unstructured":"Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, et al. Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukemia in children and young adults. Haematologica. 2024;109:3892\u2013903.","journal-title":"Haematologica"},{"key":"3067_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1269560","volume":"11","author":"P Velasco","year":"2023","unstructured":"Velasco P, Bautista F, Rubio A, Aguilar Y, Rives S, Dapena JL, et al. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Front Pediatr. 2023;11:1269560.","journal-title":"Front Pediatr"},{"key":"3067_CR16","unstructured":":: CIMA::. FICHA T\u00c9CNICA KYMRIAH 1,2 x 10e6 - 6,0 x 10e8 c\u00e9lulas en dispersi\u00f3n para perfusi\u00f3n. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181297001\/FT_1181297001.html 2025."},{"key":"3067_CR17","first-page":"259.e1","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B-cell lymphomas prior to chimeric antigen receptor T-cell therapy. Transpl Cell Ther. 2023;29:259.e1\u2013259.e10.","journal-title":"Transpl Cell Ther"},{"key":"3067_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109933","volume":"189","author":"HS Ababneh","year":"2023","unstructured":"Ababneh HS, Yee AJ, Raje NS, Martin S, Frigault MJ, Ng AK, et al. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol. 2023;189:109933.","journal-title":"Radiother Oncol"},{"key":"3067_CR19","unstructured":":: CIMA::. FICHA T\u00c9CNICA BESPONSA 1 MG POLVO PARA CONCENTRADO PARA SOLUCI\u00d3N PARA PERFUSI\u00d3N. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171200001\/FT_1171200001.html 2025."},{"key":"3067_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, Malone A, D\u00edaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137:1582\u201390.","journal-title":"Blood"},{"key":"3067_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: children\u2019s oncology group protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"key":"3067_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","volume":"37","author":"V Ceolin","year":"2023","unstructured":"Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, et al. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023;37:53\u201360.","journal-title":"Leukemia"},{"key":"3067_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1725878","volume":"16","author":"P Alcalde-Mellado","year":"2025","unstructured":"Alcalde-Mellado P, Ruiz-Maldonado V, Delgado-Serrano J, Sanoja-Flores L, Reinoso-Segura M, P\u00e9rez-Ortega L, et al. Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia. Front Immunol. 2025;16:1725878.","journal-title":"Front Immunol"},{"key":"3067_CR24","unstructured":":: CIMA::. FICHA T\u00c9CNICA Blincyto 38,5 mcg de polvo para concentrado y soluci\u00f3n para perfusi\u00f3n. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1151047001\/FT_1151047001.html 2025."},{"key":"3067_CR25","first-page":"339","volume":"45","author":"Y Pu","year":"2024","unstructured":"Pu Y, Zhou XY, Liu Y, Kong X, Han JJ, Zhang J, et al. Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2024;45:339\u201344.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"3067_CR26","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"M-E Dourthe","year":"2021","unstructured":"Dourthe M-E, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, M\u00e9chinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383\u201393.","journal-title":"Leukemia"},{"key":"3067_CR27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"RM Myers","year":"2022","unstructured":"Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:932\u201344.","journal-title":"J Clin Oncol"},{"key":"3067_CR28","first-page":"313","volume":"2","author":"LK Meyer","year":"2019","unstructured":"Meyer LK, Hermiston ML. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. Cancer Drug Resist. 2019;2:313\u201325.","journal-title":"Cancer Drug Resist"},{"key":"3067_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.773601","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhou S, Zhou T, Li X, Tang J. Targeting the incRNA DUXAP8\/miR-29a\/PIK3CA network restores doxorubicin chemosensitivity via PI3K-AKT-mTOR signaling and synergizes with inotuzumab ozogamicin in chemotherapy-resistant B-cell acute lymphoblastic leukemia. Front Oncol. 2022;12:773601.","journal-title":"Front Oncol"},{"key":"3067_CR30","doi-asserted-by":"publisher","first-page":"E222","DOI":"10.1002\/ajh.26988","volume":"98","author":"H-A Horst","year":"2023","unstructured":"Horst H-A, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, et al. CD19-negative relapse in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab: a post hoc analysis. Am J Hematol. 2023;98:E222\u2013E225.","journal-title":"Am J Hematol"},{"key":"3067_CR31","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9:2159\u201372.","journal-title":"Blood Adv"},{"key":"3067_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2022","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3:39\u201345.","journal-title":"EJHaem"},{"key":"3067_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"M-L Schubert","year":"2021","unstructured":"Schubert M-L, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34\u201348.","journal-title":"Ann Oncol"},{"key":"3067_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280580","volume":"14","author":"\u00c1 Molinos-Quintana","year":"2023","unstructured":"Molinos-Quintana \u00c1, Alonso-Saladrigues A, Herrero B, Caballero-Vel\u00e1zquez T, Gal\u00e1n-G\u00f3mez V, Panesso M, et al. Impact of disease burden and late loss of B-cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse\/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2023;14:1280580.","journal-title":"Front Immunol"},{"key":"3067_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935.","journal-title":"Front Immunol"},{"key":"3067_CR36","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1182\/bloodadvances.2024014641","volume":"8","author":"I Sahai","year":"2024","unstructured":"Sahai I, Borgman P, Yates B, Rosenzweig S, Rampertaap S, Rankin AW, et al. Incidence of preexisting B-cell aplasia in B-ALL: implications for post-CAR T-cell monitoring. Blood Adv. 2024;8:6329\u201333.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03067-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03067-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03067-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:01:57Z","timestamp":1791871317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03067-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":36,"alternative-id":["3067"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03067-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and all applicable guidelines and regulations. The study was approved by the Ethics Committee for Research with Medicinal Products of La Paz University Hospital (PI-5630). Informed consent was obtained from all patients or their legal guardians prior to inclusion in the study.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}